Ranibizumab treatment guided by disease activity was noninferior to VA stabilization-guided retreatment based on mean average BCVA change from baseline to month 1 through month 6 ( group II : +11.7 vs. group I : +11.9 ETDRS letters ; P < 0.00001 ) .